Xcout Intel
Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company develops therapies designed to protect neurons and advance treatments for patients living with age-related neurodegenerative diseases.
Subscribe to see Cognition Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cognition Therapeutics, Inc. at a glance
Cognition Therapeutics, Inc. is a biotechnology company headquartered in Purchase, United States, founded in 2007. It is publicly listed (CGTX) with a market capitalisation of $91.3M. Xcout tracks 14 named people at Cognition Therapeutics, Inc., including Lisa Ricciardi (Chief Executive Officer, President & Director).
Cognition Therapeutics, Inc. leadership
- Lisa RicciardiChief Executive Officer, President & Director
- John Brendan DoyleChief Financial Officer
- Anthony O. CaggianoChief Medical Officer
- Steven A. WeissmanVice President & Head of CMC
- Anita CornetHead of Quality
- Bobby HornCorporate Controller
8 more named people on record for Cognition Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Cognition Therapeutics, Inc. competitors
A few of Cognition Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Recognify Life Sciences is a clinical-stage biotechnology company located in California, focusing on developing treatments for cognitive impairment associated with central nervous system disorders.
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
Jocasta Neuroscience, Inc. is a preclinical-stage biotechnology company located in Scottsdale, Arizona and San Francisco, California. The company specializes in developing longevity-focused therapies for cognitive impairment.
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Get Cognition Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Cognition Therapeutics, Inc. in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access